Revytal features high-purity retatrutide in a convenient 30mg / 3ml pre-filled pen – an advanced research tool engineered for investigating next-generation metabolic regulation, multi-hormone signaling, and extreme body composition modulation.

Retatrutide (LY3437943) is a cutting-edge synthetic triple receptor agonist that simultaneously activates the GLP-1, GIP (glucose-dependent insulinotropic polypeptide), and glucagon (GCG) receptors. This unique multi-pathway approach combines the appetite-suppressing and glucose-regulating effects of GLP-1/GIP agonism with glucagon’s potential to boost energy expenditure, lipolysis, and hepatic fat utilization — positioning it as one of the most potent investigational compounds in current metabolic science.

Primary areas of research focus include:

• Profound appetite suppression and reduced caloric intake through central and gastrointestinal mechanisms
• Enhanced glucose homeostasis with glucose-dependent insulin secretion and glucagon modulation
• Significant increases in energy expenditure and fat oxidation (via glucagon receptor activation)
• Exceptional reductions in total body weight, with phase 2 data showing mean losses up to ~24% over 48 weeks
• Dramatic decreases in liver fat content (up to 82% in relevant models) and improvements in metabolic dysfunction-associated steatotic liver disease markers
• Favorable shifts in body composition, cardiometabolic parameters (lipids, inflammation, blood pressure), and insulin sensitivity

The 30mg strength in a 3ml pen offers ample capacity for extended or higher-dose experimental protocols, with retatrutide’s extended half-life of approximately 6 days supporting once-weekly administration in research settings.

Product highlights:

• Ultra-high purity retatrutide (>99% – third-party verified)
• Ready-to-use pre-filled pen injector – sterile, precise, and lab-friendly
• Advanced fatty diacid conjugation for prolonged stability and action